Drugs - Xagena.net - Update in Medicine

Search results for "Carcinoma"

Lynch syndrome: Acetylsalicylic acid reduces colorectal cancer rates by around 60%

The CAPP2 ( Colorectal Adenoma/carcinoma Prevention Programme ) trial has shown a reduction in colorectal cancer incidence of over 60% in patients at genetically increased risk who use Acetylsalicylic ... read article

Long-term use of nonaspirin anti-inflammatory drugs linked to renal cell carcinoma

Long-term use of nonaspirin anti-inflammatory drugs ( NSAIDs ) is associated with an increased risk of renal cell cancer ( RCC ). In the United States, kidney cancer is the seventh leading type of ... read article

Everolimus, new indication: treatment of patients with subependymal giant cell astrocytoma associated with tuberous sclerosis

The FDA ( Food and Drug Administration ) approved Afinitor ( Everolimus ) to treat patients with subependymal giant cell astrocytoma ( SEGA ) associated with tuberous sclerosis, a rare genetic disorde ... read article

Pazopanib, positive results in the treatment of advanced renal cell carcinoma and ovarian cancer

GlaxoSmithKline ( GSK ) has announced results from ongoing Phase II studies of Pazopanib ( Votrient ) in advanced or metastatic renal cell carcinoma ( RCC ) and ovarian cancer. Pazopanib is an ora ... read article

Iniparib improves overall survival in metastatic triple-negative breast carcinoma

Women with an aggressive subtype of metastatic breast cancer appear to live an average of almost five months longer when treated with Iniparib plus chemotherapy, compared to chemotherapy alone. A ran ... read article

Cetuximab does not add significant benefit to the NORDIC FLOX regimen in first-line treatment of metastatic colorectal carcinoma

Adding the targeted drug Cetuximab ( Erbitux ) to a three-drug chemotherapy regimen for first-line treatment of metastatic colorectal cancer does not improve response rate, progression-free survival o ... read article

Panitumumab fails to add overall survival benefit in recurrent, metastatic head and neck cancer

Adding the monoclonal anti-EGFR antibody Panitumumab ( Vectibix ) to chemotherapy did not significantly improve overall survival for patients with recurrent and/or metastatic head and neck cancer. ... read article

Afatinib improves progression-free in lung adenocarcinoma patients whose cancer progressed after treatment with EGFR inhibitors

Lung cancer patients who have already been treated with the EGFR inhibitors Erlotinib or Gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated ... read article

MLN8237, an investigational drug shows promise against ovarian cancer resistant or refractory to Platinum-based chemotherapy

Researchers at Dana-Farber Cancer Institute in the USA reported the results of the single-agent trial of the drug, called MLN8237, developed as a treatment for ovarian cancer. MLN8237 selectively i ... read article

Gefitinib does not improve overall survival in patients with advanced NSCLC with EGFR activating mutations

Data from the IPASS study showed that overall survival ( OS ) was similar, with no significant difference, between Gefitinib ( Iressa ) and Carboplatin / Paclitaxel ( doublet chemotherapy ) in the ove ... read article

Metastatic renal-cell carcinoma: switch to metronomic chemotherapy could offer new treatment option

A new multi-targeted chemo-switch drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma ( RCC ), a disease with few treatment ... read article

Advanced kidney cancer: Sorafenib shrinks tumor prior to surgery

Physicians who conducted a pilot study at University of North Carolina ( UNC ) Lineberger Comprehensive Cancer Center found that therapy before surgery with the drug Sorafenib ( Nexavar ) can reduce t ... read article

Advances in renal cell carcinoma management

Renal cell carcinoma ( RCC ) accounts for about 3% of all solid tumours in adults, and worldwide, more than 200.000 new cases and 100.000 deaths result each year from this malignancy. In contrast ... read article

Dutasteride reduces risk of prostate carcinoma diagnosis in high-risk men

Dutasteride ( Avodart ) has shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease. The results are reported in the New England Journal of ... read article

Parkinson's disease: Stalevo linked to possible development of prostate carcinoma

The FDA ( Food and Drug Administration ) is evaluating clinical trial data that may suggest that patients taking Stalevo, a Parkinson's disease medication, may be at an increased risk for developing p ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article